Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Goodwill (2017 - 2025)

Avalo Therapeutics filings provide 9 years of Goodwill readings, the most recent being $10.5 million for Q4 2025.

  • On a quarterly basis, Goodwill changed 0.02% to $10.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 0.02% change, with the full-year FY2025 number at $10.5 million, changed 0.02% from a year prior.
  • Goodwill hit $10.5 million in Q4 2025 for Avalo Therapeutics, roughly flat from $10.5 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $14.4 million in Q1 2021 to a low of $10.5 million in Q4 2025.
  • Median Goodwill over the past 5 years was $14.4 million (2021), compared with a mean of $12.7 million.
  • Biggest five-year swings in Goodwill: changed 0.0% in 2021 and later dropped 27.11% in 2023.
  • Avalo Therapeutics' Goodwill stood at $14.4 million in 2021, then changed by 0.0% to $14.4 million in 2022, then dropped by 27.11% to $10.5 million in 2023, then changed by 0.0% to $10.5 million in 2024, then decreased by 0.02% to $10.5 million in 2025.
  • The last three reported values for Goodwill were $10.5 million (Q4 2025), $10.5 million (Q3 2025), and $10.5 million (Q2 2025) per Business Quant data.